Background. Worldwide, lung cancer is one of the leading causes of cancer death. Nevertheless, new therapeutic agents have been developed to treat lung cancer that could change this mortality-rate. Interestingly, incredible advances have occurred in recent years in the development and application of nanotechnology in the detection, diagnosis, and treatment of lung cancer.
Aim. Nanoparticles have the ability to incorporate multiple drugs and targeting agents and therefore lead to an improved bioavailability, sustained delivery, solubility, and intestinal absorption.
Relevance for patients. This review briefly summarizes the latest innovations in therapeutic nanomedicine in lung cancer with examples on magnetic, lipid and polymer nanoparticles. Emphasis will be placed on future studies and ongoing clinical trials in this field.
1. Radiation Oncology Department. Hospital Central de la Defensa Gómez Ulla. Madrid. Madrid. Spain.
2. Radiation Oncology Department. Hospital Universitario Ramón y Cajal. Madrid, Spain.
Radiation Oncology. Hospital Universitario Ramón y Cajal, Madrid. Carretera de Colmenar Viejo Km 9,100. 28034, Madrid, Spain.
Michal Heger Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China